Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.

Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. Abstract Text:

    michelle a lowesMichelle A Lowes,francesca chamianFrancesca Chamian,maria v abelloMaria V Abello,craig leonardiCraig Leonardi,wolfgang dummerWolfgang Dummer,kim pappKim Papp,james g kruegerJames G Krueger,

    BACKGROUND: Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur. CASE PRESENTATIONS: We present a group of 15 patients who developed inflammatory papules while on efalizumab therapy (Raptiva, Genentech Inc, anti-CD11a). Immunohistochemistry showed that there were increased CD11b+, CD11c+ and iNOS+ cells (myeloid leukocytes) in the papules, with relatively few CD3+ T cells. While efalizumab caused a decreased expression of CD11a on T cells, other circulating leukocytes from patients receiving this therapy often showed increased CD11b and CD11c. In the setting of an additional stimulus such as skin trauma, this may predispose to increased trafficking into the skin using these alternative beta2 integrins. In addition, there may be impaired immune synapse formation, limiting the development of these lesions to small papules. There is little evidence for these papular lesions being "allergic" in nature as there are few eosinophils on biopsy, and they respond to minimal or no therapy even if efalizumab is continued. CONCLUSION: We hypothesize that these papules may represent a unique type of "mechanistic" inflammatory reaction, seen only in the context of drug-induced CD11a blockade, and not during the natural disease process.

    Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. Publishing Authors By Initials

    ma lowesMA Lowes,f chamianF Chamian,mv abelloMV Abello,c leonardiC Leonardi,w dummerW Dummer,k pappK Papp,jg kruegerJG Krueger,

    For similar cells: blood cells: leukocytes: leukocytes, mononuclear: lymphocytes: t-lymphocytes research abstracts see: cells: blood cells: leukocytes: leukocytes, mononuclear: lymphocytes: t-lymphocytes research

    PUBMED ID PMID:

    MEDLINE DATE:

    Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. Journal Published:

    PUBLICATION TYPE: Research Support, N.I.H., Extr

    Journal: BMC dermatology

    VOLUME: 7

    Page Numbers: 2

    Journal Abbreviation: BMC Dermatol.

    ISSN: 1471-5945

    DAY: 26

    MONTH: 02

    YEAR: 2007

    Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 100968541

    Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. Keywords Mesh Terms:

    KEYWORDS: T-Lymphocytes

    MESH TERMS: pathology

    Chemical & Substance for Abstract: Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. Information

    Substance Name: Nitric Oxide Synthase Type II

    Registry Number: EC 1.14.13.39

    Grant and Affiliation Information for Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.

    AFFILIATION: Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA. jgk@rockefeller.edu.

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY: United States NIAID

    GRANT: R01 AI-49572

    ACRONYM: AI

    MEDLINETA: BMC Dermatol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Eruptive papules during efalizumab anti-CD11a therapy of psoriasis vulgaris: a case series Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News